Pfizer Identifies Synexus' South African Clinical Research Sites as INSPIRE Sites - First in Africa MANCHESTER, England, June 12, 2013 /CNW/ - Three of Synexus' South African dedicated clinical research centres Stanza, Watermeyer and Nyeleti have been identified by Pfizer as meeting the exacting standards that the company demands to join a worldwide network of INSPIRE sites which must be both highly productive and effective. INSPIRE, which stands for Investigator Networks, Site Partnerships and Infrastructure for Research Excellence, means that these sites have early access to Pfizer's portfolio data and advanced information regarding the clinical trials to be sponsored by Pfizer. They are also involved in publications in scientific journals, protocol design, advisory boards and the sharing of best practice across the INSPIRE network. Synexus, which is the world's largest multi-national company focused on the recruitment and running of clinical trials, already has an INSPIRE site in Wroclaw Poland. Tebogo Sebata, Investigator Site Development and Support Lead, Pfizer Global commented, "We are really delighted that we have been able to identify these sites and add them to our INSPIRE network. We put in place the INSPIRE programme so that we can work with the best sites across the world. Centres which have real expertise in the science of clinical trials, the infrastructure support that is necessary, proven recruitment strategies and the in depth knowledge can help us maximize our development programmes going forward." Dr Sanet Aspinall, Managing Director of Synexus South Africa, commented, "We are thrilled to have been invited to become part of the INSPIRE network. We have had to go through an exhaustive assessment programme which looked at our previous experience, expertise across a range of therapeutic areas, infrastructure and resources and effective recruitment strategies. This is not only excellent for our company but for South Africa as it shows that it is a very good place in which to carry out clinical trials." Dr Glynis Neagle, Chief Medical Officer for Synexus concluded, "We are really focussed on providing our clients with quality patients and data. To do this, we are training our doctors and clinical staff in the medical science of the therapy areas we focus on; cardiovascular, metabolic (diabetes and obesity), bone, respiratory, infectious diseases and CNS (dementia and pain). Our investigators are experts in clinical trials and apply this knowledge to each trial which gives added value to clients." Simon Vane Percy email@example.com + 44-(0)1737-821-890 SOURCE: SYNEXUS To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/June2013/12/c7453.html CO: SYNEXUS -0- Jun/12/2013 12:38 GMT
Pfizer Identifies Synexus' South African Clinical Research Sites as INSPIRE Sites - First in Africa
Press spacebar to pause and continue. Press esc to stop.